-
EP4408891
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4408891
| EP4408891 - ANTIBODIES TARGETING BAFF-R AND USE THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 05.07.2024 Database last updated on 21.03.2026 | |
| Former | The international publication has been made Status updated on 07.04.2023 | Most recent event Tooltip | 20.03.2026 | Change - applicant | published on 22.04.2026 [2026/17] | Applicant(s) | For all designated states Dragonfly Therapeutics, LLC 180 3rd Ave., Sixth Floor Waltham, MA 02451 / US | [2026/17] |
| Former [2024/32] | For all designated states Dragonfly Therapeutics, Inc. 180 3rd Avenue, Sixth Floor Waltham, MA 02451 / US | Inventor(s) | 01 /
FISCHER, Benjamin Waltham, MA 02451 / US | 02 /
HEIN, Pyae, P. Waltham, MA 02451 / US | 03 /
IVANOV, Alexander Waltham, MA 02451 / US | 04 /
LI, Xinbi Waltham, MA 02451 / US | 05 /
SCHNEIDER, Matthew Waltham, MA 02451 / US | [2024/32] | Representative(s) | Mathys & Squire 32 London Bridge Street The Shard London SE1 9SG / GB | [N/P] |
| Former [2024/32] | Redhouse, Juliet Lauren, et al Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB | Application number, filing date | 22877491.5 | 27.09.2022 | [2024/32] | WO2022US77068 | Priority number, date | US202163250092P | 29.09.2021 Original published format: US 202163250092 P | [2024/32] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2023056243 | Date: | 06.04.2023 | Language: | EN | [2023/14] | Type: | A1 Application with search report | No.: | EP4408891 | Date: | 07.08.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.04.2023 takes the place of the publication of the European patent application. | [2024/32] | Search report(s) | International search report - published on: | US | 06.04.2023 | (Supplementary) European search report - dispatched on: | EP | 16.07.2025 | Classification | IPC: | C07K16/28, A61K39/39, A61P29/00, A61P35/00 | [2024/32] | CPC: |
C07K16/2878 (EP,IL,KR,US);
A61P29/00 (EP,IL);
A61K40/11 (KR,US);
A61K40/15 (US);
A61K40/31 (US);
A61K40/33 (KR,US);
A61K40/41 (US);
A61K47/6803 (KR);
A61K47/68031 (US);
A61K47/68033 (US);
A61K47/68035 (US);
A61K47/68037 (US);
A61K47/6807 (US);
A61K47/6849 (US);
A61P35/00 (EP,IL,KR);
A61P37/00 (KR);
C07K14/525 (US);
C07K14/5406 (US);
C07K14/5428 (US);
C07K14/5434 (US);
C07K14/5443 (US);
C07K14/55 (US);
C07K14/56 (US);
C07K14/7051 (KR);
C07K16/2809 (KR,US);
C12N5/0636 (KR,US);
C12N5/0646 (US);
C07K2317/31 (EP,IL,KR,US);
C07K2317/622 (EP,IL,KR);
C07K2317/73 (EP,IL);
C07K2317/76 (EP,KR);
C07K2317/92 (EP,IL,KR,US);
C07K2319/02 (KR,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/32] | Title | German: | GEGEN BAFF-R GERICHTETE ANTIKÖRPER UND VERWENDUNG DAVON | [2024/32] | English: | ANTIBODIES TARGETING BAFF-R AND USE THEREOF | [2024/32] | French: | ANTICORPS CIBLANT BAFF-R ET LEUR UTILISATION | [2024/32] | Entry into regional phase | 27.03.2024 | National basic fee paid | 27.03.2024 | Search fee paid | 27.03.2024 | Designation fee(s) paid | 27.03.2024 | Examination fee paid | Examination procedure | 27.03.2024 | Examination requested [2024/32] | 31.10.2024 | Amendment by applicant (claims and/or description) | 04.02.2026 | Date on which the examining division has become responsible | 20.02.2026 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time | Fees paid | Renewal fee | 08.04.2024 | Renewal fee patent year 03 | 29.09.2025 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I] US2020190204 (QIN HONG et al.) [I] 1-17 * figures 1C-E, 11; example 1 * * figures 2A,C, 3A, 12, 13; example 1 * * figure 14; example 1 * * example 2; table 1 * * figures 4B,C, 6; example 1 * * figure 20; example 2 * | [I] WO2021163989 (YINNUOLAI BIOTECH LTD et al.) [I] 1-17 * table 1 * * figure 1A * * table 3 * * figure 3 * | [I] US9382326 (HEUSSER CHRISTOPH et al.) [I] 1-17 * example 1; table 2 * * example 1; table 3 * * example 1; table 4 * * example 1; tables 5,6 * * example 1; table 7 * * figure 2; example 3 * | [I] WO2006073941 (GENENTECH INC et al.) [I] 1-17 * example 2; table 3 * * figure 10; example 3 * * table; page 124; example 4 * * figure 19; example 5 * * figure 23; example 7 * * example 8; tables 11-13 * * figure 29; example 11 * | [I] LEE CHINGWEI V ET AL: "Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells", BLOOD, ELSEVIER, AMSTERDAM, NL, vol. 108, no. 9, 1 November 2006 (2006-11-01), pages 3103 - 3111, XP002509032, ISSN: 0006-4971, [retrieved on 20060713], DOI: 10.1182/BLOD-2006-03-011031 [I] 1-17 * figure 2B * * figure 6 * DOI: http://dx.doi.org/10.1182/blod-2006-03-011031 | [I] MCWILLIAMS EMILY M. ET AL: "Abstract", BLOOD ADVANCES, vol. 3, no. 3, 12 February 2019 (2019-02-12), pages 447 - 460, XP055853252, ISSN: 2473-9529, Retrieved from the Internet DOI: http://dx.doi.org/10.1182/bloodadvances.2018025684 | International search | [A] US2018251564 (COSENZA MARTA et al.) [A] 1, 4, 5, 7, 13 * entire document * | [A] WO2010072741 (ASTRAZENECA AB et al.) [A] 1, 4, 5, 7, 13 * entire document * | [A] WO2009120922 (ZYMOGENETICS INC et al.) [A] 1, 4, 5, 7, 13 * entire document * | [A] US2020190204 (QIN HONG et al.) [A] 1, 4, 5, 7, 13 * entire document * |